Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.62 |
| ▸ | KDR | P35968 | 8/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.56 |
| ▸ | MET | P08581 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | TEK | Q02763 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | MERTK | Q12866 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12663554 | 0.91 | AXL (0.60) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL21217949 | 0.88 | KDR (0.54) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL12663553 | 0.87 | KDR (0.59) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL12663608 | 0.84 | AXL (0.54) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL12664714 | 0.81 | AXL (0.54) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL12663606 | 0.81 | AXL (0.51) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL25502393 | 0.80 | AXL (0.95) | AXLKDRMETAURKALCK | |
| SCHEMBL19196875 | 0.80 | PDGFRA (0.56) | KDRPDGFRAFGFR2SRCTGFBR1 | |
| SCHEMBL29558136 | 0.78 | AXL (0.65) | AXLKDRPDGFRAMETAURKA | |
| SCHEMBL22106609 | 0.78 | AXL (0.70) | AXLKDRPDGFRAMETAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192619-A1 | Processes for the Preparation of a Kinase Inhibitor | EXELIXIS, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192619-A1 | Processes for the Preparation of a Kinase Inhibitor | MET, HGF, BRAF | AXL 421/4885KDR 408/4885PDGFRA 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.